Meeting Report
Banff 2011 Meeting Report: New Concepts in Antibody-Mediated Rejection

https://doi.org/10.1111/j.1600-6143.2011.03926.xGet rights and content
Under a Creative Commons license
open archive

The 11th Banff meeting was held in Paris, France, from June 5 to 10, 2011, with a focus on refining diagnostic criteria for antibody-mediated rejection (ABMR). The major outcome was the acknowledgment of C4d-negative ABMR in kidney transplants. Diagnostic criteria for ABMR have also been revisited in other types of transplants. It was recognized that ABMR is associated with heterogeneous phenotypes even within the same type of transplant. This highlights the necessity of further refining the respective diagnostic criteria, and is of particular significance for the design of randomized clinical trials. A reliable phenotyping will allow for definition of robust end-points. To address this unmet need and to allow for an evidence-based refinement of the Banff classification, Banff Working Groups presented multicenter data regarding the reproducibility of features relevant to the diagnosis of ABMR. However, the consensus was that more data are necessary and further Banff Working Group activities were initiated. A new Banff working group was created to define diagnostic criteria for ABMR in kidneys independent of C4d. Results are expected to be presented at the 12th Banff meeting to be held in 2013 in Brazil. No change to the Banff classification occurred in 2011.

Key words:

Allograft rejection
allograft transplantation
antibody-mediated rejection
Banff classification

Abbreviations:

ABMR
antibody-mediated rejection
BWG
Banff Working Group
CXM+
positive cross-match
CNI
calcineurin inhibitor
DSA
donor-specific antibody
FDA
Food and Drug Administration
IFTA
interstitial fibrosis and tubular atrophy
MI
microcirculation inflammation, i.e. glomerulitis and/or capillaritis
TCMR
T-cell-mediated rejection
TG
transplant glomerulopathy
V-Score
Banff intimal arteritis score
VCA
vascularized composite allograft

Cited by (0)